$LYEL filed an 8-K with results (Item 2.02) at 4:14 PM ET on Wed, Nov 4.
Vote
LYEL
Lyell Immunopharma, Inc.About LYEL
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Why it moved
Lyell Immunopharma raised $80 million to advance ronde-cel · per company
Sources: GlobeNewswire · BioPharmaWatch
AI generated · Not investment advice
Why it moved
Lyell Immunopharma raised $80 million to advance ronde-cel · per company
Confirmed: from the company’s own release or SEC filing.
Sources: GlobeNewswire · BioPharmaWatch
Written 11:30 AM ET · last check 7:30 PM ET
AI generated · May contain errors · Not investment adviceSummarized from public reports · Sources linkedSign up free to see this.
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Sentiment
No sentiment yet
Votes and Bull · Bear posts, 24h. At least 5 are needed.
How do you feel about LYEL?
Board · 0 threads
Open board ›Community opinions, not advice. Posts with a target get a receipt. How receipts work ›